Abstract | Keywords | Export | Availability | Bookmark

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Tissue fibrosis may occur for unknown causes or be the consequence of many pathological conditions including chronic inflammatory or infectious diseases, autoimmune disorders, graft rejection, or malignancy. On the other hand, malignant tumors have been identified in fibrotic tissues decades ago, and now accumulating evidence suggests that fibrotic lesions enhance the risk of cancer in several organs such as liver, lungs, and breast. Disruption of an organ parenchymal cells and of its normal structural scaffold during tissue fibrogenesis appears to induce loss of cell polarity, promoting uncontrolled cell proliferation that may eventually lead to cancer development. Many cellular and molecular abnormalities including aberrant expression of microRNAs, genetic and epigenetic alterations, evasion or delayed apoptosis, unregulated intracellular signal pathways, and dysregulation or defective intercellular communications have been proposed to explain this link between fibrogenesis and carcinogenesis. However, the precise mechanisms of this fibrosis-to-cancer transition remain unclear. This book presents a collection of reviews and original articles summarizing recent advances in understanding the molecular mechanisms of cancer development in fibrotic organs.

bleomycin --- n/a --- regeneration --- antitumor efficacy --- lung cancer --- SOX2 --- leiomyosarcoma --- lung cancer (LC) --- nanoparticles --- cytokines --- hepatocellular carcinoma --- metabolic reprogramming --- hepatic stellate cells --- angiogenesis --- transforming growth factor-? --- anaplastic lymphoma kinase --- idiopathic pulmonary fibrosis --- growth factor --- pathogenesis --- cancer-associated fibroblasts --- fibrosis --- lipopolysaccharide --- DHA --- lncRNA --- SREBP-1 --- YAP --- protein S --- non-small cell lung cancer (NSCLC) --- omega-3 fatty acid --- inflammation --- metastasis --- clinical symptoms --- miRNA --- smooth muscle tumor of uncertain malignant potential --- Wnt --- interstitial fluid pressure --- heterogeneity --- hepatocytes --- myometrium --- tumor necrosis factor ? --- tumor --- tumor microenvironment --- extracellular matrix --- TAZ --- carcinogenesis --- cystic formation --- pulmonary fibrosis --- HBV --- cytokine --- genetic instability --- diagnosis --- EMT --- crizotinib --- Hippo pathway --- GPR120 --- marker --- HCV --- non-alcoholic steatohepatitis --- pathology --- common pathways --- apoptosis --- type I collagen --- GPR40 --- acute lung injury --- uterine fibroid --- renal injury --- pathophysiology --- reactive oxygen species --- immunohistochemistry --- SMAD --- butylidenephthalide --- leiomyoma --- cirrhosis --- Erk1/2 --- targeted therapy --- TGF-? --- mechanotransduction --- therapy --- breast cancer --- hepatocellular carcinoma (HCC) --- hepatic stellate cells (HSCs) --- idiopathic pulmonary fibrosis (IPF) --- cancer-associated fibroblasts (CAFs) --- cancer --- signal pathway --- tumor stiffness